AUTHOR=Hutka Barbara , Lázár Bernadette , Tóth András S. , Ágg Bence , László Szilvia B. , Makra Nóra , Ligeti Balázs , Scheich Bálint , Király Kornél , Al-Khrasani Mahmoud , Szabó Dóra , Ferdinandy Péter , Gyires Klára , Zádori Zoltán S. 

TITLE=The Nonsteroidal Anti-Inflammatory Drug Ketorolac Alters the Small Intestinal Microbiota and Bile Acids Without Inducing Intestinal Damage or Delaying Peristalsis in the Rat

JOURNAL=Frontiers in Pharmacology

VOLUME=12

YEAR=2021

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.664177

DOI=10.3389/fphar.2021.664177

ISSN=1663-9812

ABSTRACT=<p><bold>Background:</bold> Nonsteroidal anti-inflammatory drugs (NSAIDs) induce significant damage to the small intestine, which is accompanied by changes in intestinal bacteria (dysbiosis) and bile acids. However, it is still a question of debate whether besides mucosal inflammation also other factors, such as direct antibacterial effects or delayed peristalsis, contribute to NSAID-induced dysbiosis. Here we aimed to assess whether ketorolac, an NSAID lacking direct effects on gut bacteria, has any significant impact on intestinal microbiota and bile acids in the absence of mucosal inflammation. We also addressed the possibility that ketorolac-induced bacterial and bile acid alterations are due to a delay in gastrointestinal (GI) transit.</p><p><bold>Methods:</bold> Vehicle or ketorolac (1, 3 and 10 mg/kg) were given to rats by oral gavage once daily for four weeks, and the severity of mucosal inflammation was evaluated macroscopically, histologically, and by measuring the levels of inflammatory proteins and claudin-1 in the distal jejunal tissue. The luminal amount of bile acids was measured by liquid chromatography-tandem mass spectrometry, whereas the composition of microbiota by sequencing of bacterial 16S rRNA. GI transit was assessed by the charcoal meal method.</p><p><bold>Results:</bold> Ketorolac up to 3 mg/kg did not cause any signs of mucosal damage to the small intestine. However, 3 mg/kg of ketorolac induced dysbiosis, which was characterized by a loss of families belonging to Firmicutes (<italic>Paenibacillaceae</italic>, <italic>Clostridiales Family XIII</italic>, <italic>Christensenellaceae</italic>) and bloom of <italic>Enterobacteriaceae</italic>. Ketorolac also changed the composition of small intestinal bile by decreasing the concentration of conjugated bile acids and by increasing the amount of hyodeoxycholic acid (HDCA). The level of conjugated bile acids correlated negatively with the abundance of <italic>Erysipelotrichaceae</italic>, <italic>Ruminococcaceae</italic>, <italic>Clostridiaceae 1</italic>, <italic>Muribaculaceae</italic>, <italic>Bacteroidaceae</italic>, <italic>Burkholderiaceae</italic> and <italic>Bifidobacteriaceae</italic>. Ketorolac, under the present experimental conditions, did not change the GI transit.</p><p><bold>Conclusion:</bold> This is the first demonstration that low-dose ketorolac disturbed the delicate balance between small intestinal bacteria and bile acids, despite having no significant effect on intestinal mucosal integrity and peristalsis. Other, yet unidentified, factors may contribute to ketorolac-induced dysbiosis and bile dysmetabolism.</p>